Advertisement
Advertisement
U.S. markets close in 3 hours 52 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Assembly Biosciences, Inc. (ASMB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.8380+0.0380 (+2.11%)
As of 12:07PM EST. Market open.
Advertisement

Assembly Biosciences, Inc.

331 Oyster Point Boulevard
Fourth Floor
South San Francisco, CA 94080
United States
833 509 4583
https://www.assemblybio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees139

Key Executives

NameTitlePayExercisedYear Born
Dr. John G. McHutchison A.O., FRACP, M.D.CEO, Pres & Director1.44MN/A1957
Mr. Jason A. OkazakiChief Operating Officer703.27kN/A1976
Dr. William E. Delaney IV, Ph.D.Chief Scientific Officer450.87kN/A1972
Dr. Uri A. Lopatin M.D.Co-Founder and Clinical & Scientific AdvisorN/AN/A1972
Dr. Adam ZlotnickCo-Founder, Chief Scientific Advisor and Chair of Hbv & Virology Science Advisory BoardN/AN/AN/A
Mr. Michael P. SamarCFO & Principal Accounting OfficerN/AN/A1972
Ms. Lauren GlaserSr. VP of Investor Relations & Corp. AffairsN/AN/AN/A
Ms. Jennifer A. Troia MHROD, SHRM-SCP, SPHRChief HR OfficerN/AN/AN/A
Dr. Richard J. ColonnoSr. AdvisorN/AN/A1950
Dr. Tharaknath RaoHead of Microbiome Clinical Devel. & Sr. VPN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection. Its product candidates include Vebicorvir to treat patients with chronic HBV infection; ABI-H2158, which is in Phase II clinical study for chronic HBV infection; ABI-H3733 that has completed Phase Ia clinical study for the treatment of HBV. The company has collaboration agreements with Allergan Pharmaceuticals International Limited; BeiGene, Ltd.; and Arbutus Biopharma Corporation, as well as strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. It also has a clinical collaboration agreement with Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in South San Francisco, California.

Corporate Governance

Assembly Biosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement